SecBot SecBot

VKTX

Viking Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001607678 Biotech & Drug Discovery
$26.80 −2.42 (−8.28%)
Nov 16 4:00 PM ET · prev $29.22
Market cap
$3.5B
Mid cap
Consensus
Buy
89% Buy or better · 27 analysts
Median target
$95.00
+254% · range $34.00–125.00
1 year
−29.9%
from $38.22 · Nov 17
30 days
+7.0%
from $25.05
52-week range
$24.21–42.13
−36% from high · low Oct 26
Avg volume 20D
4.19M
shares / day
Short interest
24.16M
≈18.9% of shares · −5.4%
Days to cover
5.4
at average volume
Insider net
−$6.1M
1 buyer · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 2 exits
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 10 reports · 90 days
Balance 4 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $149.9K at an average $33.50. 3 insiders sold $6.3M. Price is 20% below their cost.

  • InstitutionsMIXED

    Q3 2026: 38 added (0 new), 27 trimmed or exited.

  • AnalystsBULLISH

    24 of 27 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −5.4% to 24.16M shares. 5.4 days to cover, ≈18.9% of shares.

  • TrendRANGE

    8% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 24.

Who's buying

13F· Q3 2026
0
new positions
2
exits
FundMoveSharesValue
FMR LLCADD9,847,017$321.0M
BARCLAYS PLCDOUBLED872,696$28.4M
Bank of New York Mellon CorpADD686,019$22.4M
PRINCIPAL FINANCIAL GROUP INCADD670,787$21.9M
JANE STREET GROUP, LLCTRIM488,443$15.9M
Pictet Asset Management Holding SATRIM486,586$15.9M
MARSHALL WACE, LLPDOUBLED482,060$15.7M
DIMENSIONAL FUND ADVISORS LPTRIM396,375$12.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 89% rate it Buy or better
Strong Buy9Buy15Hold3Sell0Strong Sell0
12-month targets · 19 analysts

Price is below the lowest target. Median implies +254%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 30, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 20, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 15, 2026UBS
INITIATE
INITIATEBuy
Oct 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 23, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Aug 11, 2026JP Morgan
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$149.9K
bought · 1 insider
$6.3M
sold · 3 insiders
−20.0%
vs their $33.50 cost
DateInsiderTypeValue
Aug 1, 2026
Kelly-Gemmell Dorothy Elizabeth
Director
Aug 1, 2026
AWARD40,800 sh
Aug 1, 2026
Kelly-Gemmell Dorothy Elizabeth
Director
Aug 1, 2026
AWARD6,333 sh
Jul 29, 2026
Mancini Marianna
Chief Operating Officer
Jul 29, 2026
SELL$609.6K
Jul 29, 2026
ZANTE GREG
Chief Financial Officer
Jul 29, 2026
SELL$710.1K
Jul 29, 2026
Lian Brian
President & CEO
Jul 29, 2026
SELL$4.9M
Jul 28, 2026
Mancini Marianna
Chief Operating Officer
Jul 28, 2026
AWARD31,667 sh
Jul 28, 2026
ZANTE GREG
Chief Financial Officer
Jul 28, 2026
AWARD31,667 sh
Jul 28, 2026
Lian Brian
President & CEO
Jul 28, 2026
AWARD221,667 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
24,163,022
shares short
-5.4%
vs prior settlement
5.4
days to cover
≈18.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 9,539,067 shares of Viking…
SC 13G/A · Impact 3/10
Nov 3, 2026 Other
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clini
Oct 28, 2026 SEC
Viking Therapeutics reported Q3 2026 net loss of $183.2M ($1.55/share), wider than the $90.8M loss in Q3 2025, driven…
8-K · Impact 5/10
Oct 23, 2026 SEC
Viking Therapeutics' Q3 2026 institutional 13F cluster shows net selling pressure: 4 asset managers trimmed positions…
INST-CLUSTER · Impact 4/10
Sep 30, 2026 Inst.
FMR LLC · ADD
9,847,017 shares ($321.0M)
Sep 30, 2026 Inst.
BARCLAYS PLC · DOUBLED
872,696 shares ($28.4M)
Aug 1, 2026 Insider
Kelly-Gemmell Dorothy Elizabeth was granted 40,800 shares
Director
Aug 1, 2026 Insider
Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent
Nov 3, 2026
Press release
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on…
Oct 28, 2026
Earnings result
VKTX Q3 2026 Earnings: EPS $-1.55 (-42.6% vs est)
Oct 21, 2026
Earnings
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc…
Oct 20, 2026
Earnings date
VKTX Q3 2026 Earnings After Market Close, 2026-10-20
Oct 14, 2026
Press release
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/…

SecBot reports

13 filings · 1 bullish · 4 bearish · 1 mixed · 7 neutral
All VKTX filing & press-release reports (13)